Clinical Trial

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Study acronym: OVATION-3
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2025-04-01; most recent amendment 2026-07-15.
Status change: Not Yet Recruiting → Recruiting 2025-07-01
Trial Details
NCT Number NCT06915025
Lead Sponsor Imunon
Conditions Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Enrollment 500 participants
Start Date 2025-07-09
Primary Completion 2032-10-31 (estimated)
Study Completion 2032-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-04